Posted by Michael Wonder on 29 Oct 2020
European Commission grants marketing authorisation for Arikayce liposomal 590 mg nebuliser dispersion for the treatment of NTM lung infections caused by MAC in adult non-CF patients with limited treatment options
28 October 2020 - Arikayce is the first and only therapy approved in both the European Union and United States for this difficult to treat condition.
Insmed today announced that the European Commission has granted marketing authorization for Arikayce liposomal 590 mg nebuliser dispersion for the treatment of non-tuberculous mycobacterial lung infections caused by Mycobacterium avium complex in adults with limited treatment options who do not have cystic fibrosis. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
